Effects Of Concussions In Football Players.
The US National Institutes of Health is teaming up with the National Football League on on into the long-term things of repeated go injuries and improving concussion diagnosis. The projects will be supported largely through a $30 million bestowal made last year to the Foundation for the National Institutes of Health by the NFL, which is wrestling with the end of concussions and their impact on current and former players cellulitesolution.herbalous.com. There's growing responsibility about the potential long-term effects of repeated concussions, particularly among those most at risk, including football players and other athletes and members of the military.
Current tests can't reliably diagnosis concussion. And there's no headway to forebode which patients will recover quickly, suffer long-term symptoms or display a progressive brain disease called chronic traumatic encephalopathy (CTE), according to an NIH also pressurize statement released Monday, Dec 2013 antehealth. "We need to be able to predict which patterns of mischief are rapidly reversible and which are not.
This program will help researchers get closer to answering some of the important questions about concussion for our maiden who play sports and their parents," Story Landis, director of the National Institute of Neurological Disorders and Stroke (NINDS), said in the telecast release. Two of the projects will show in $6 million each and will focus on determining the extent of long-term changes that occur in the brain years after a wit injury or after numerous concussions. They will involve researchers from NINDS, the National Institute of Child Health and Human Development and collegiate medical centers.
Wednesday, 7 June 2017
Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy
Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy.
In a decree that seems to chip the prevailing wisdom that any form of hormone replacement treatment raises the risk of breast cancer, a new look at some old data suggests that estrogen-only hormone remedy might protect a small subset of postmenopausal women against the disease. "Exogenous estrogen such as hormone remedial programme is actually protective" in women who have a low risk for developing core tumors, said study author Dr Joseph Ragaz, a medical oncologist and clinical professor in the School of Population & Public Health at the University of British Columbia in Vancouver howporstarsgrowit.com. With his colleagues, Ragaz took another glance at material from the Women's Health Initiative (WHI) study, a public trial that has focused on ways to prevent breast and colorectal cancer, as well as nub disease and fracture risk, in postmenopausal women.
The team planned to present its findings Thursday at the San Antonio Breast Cancer Symposium in Texas. Research presented at medical meetings is not analyzed by shell experts, atypical studies that appear in peer-reviewed medical journals, and all such findings should be considered preliminary tryvimax. Launched in 1991, the WHI includes more than 161000 US women between the ages of 50 and 79.
Two groups were vicinage of the side - women who had had hysterectomies and took estrogen abandoned as hormone replacement therapy and a group that took estrogen plus progestin hormone replacement therapy. The bloc therapy trial was halted in 2002 after it became clear those women were at increased gamble for heart disease and breast cancer.
In the new look at the estrogen-only group "we looked at women who did not have high-risk features". They found that women with no old history of benign teat disease had a 43 percent reduction breast cancer risk on estrogen; women with no issue history with a first-degree relative with breast cancer had a 32 percent risk reduction and women without former hormone use had a 32 percent reduced risk.
In a decree that seems to chip the prevailing wisdom that any form of hormone replacement treatment raises the risk of breast cancer, a new look at some old data suggests that estrogen-only hormone remedy might protect a small subset of postmenopausal women against the disease. "Exogenous estrogen such as hormone remedial programme is actually protective" in women who have a low risk for developing core tumors, said study author Dr Joseph Ragaz, a medical oncologist and clinical professor in the School of Population & Public Health at the University of British Columbia in Vancouver howporstarsgrowit.com. With his colleagues, Ragaz took another glance at material from the Women's Health Initiative (WHI) study, a public trial that has focused on ways to prevent breast and colorectal cancer, as well as nub disease and fracture risk, in postmenopausal women.
The team planned to present its findings Thursday at the San Antonio Breast Cancer Symposium in Texas. Research presented at medical meetings is not analyzed by shell experts, atypical studies that appear in peer-reviewed medical journals, and all such findings should be considered preliminary tryvimax. Launched in 1991, the WHI includes more than 161000 US women between the ages of 50 and 79.
Two groups were vicinage of the side - women who had had hysterectomies and took estrogen abandoned as hormone replacement therapy and a group that took estrogen plus progestin hormone replacement therapy. The bloc therapy trial was halted in 2002 after it became clear those women were at increased gamble for heart disease and breast cancer.
In the new look at the estrogen-only group "we looked at women who did not have high-risk features". They found that women with no old history of benign teat disease had a 43 percent reduction breast cancer risk on estrogen; women with no issue history with a first-degree relative with breast cancer had a 32 percent risk reduction and women without former hormone use had a 32 percent reduced risk.
Subscribe to:
Posts (Atom)